WO2008070833A3 - Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs - Google Patents

Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs Download PDF

Info

Publication number
WO2008070833A3
WO2008070833A3 PCT/US2007/086779 US2007086779W WO2008070833A3 WO 2008070833 A3 WO2008070833 A3 WO 2008070833A3 US 2007086779 W US2007086779 W US 2007086779W WO 2008070833 A3 WO2008070833 A3 WO 2008070833A3
Authority
WO
WIPO (PCT)
Prior art keywords
stat1
stat3
peptidomimetices
peptidomimetics
anticancer drugs
Prior art date
Application number
PCT/US2007/086779
Other languages
French (fr)
Other versions
WO2008070833A2 (en
WO2008070833A9 (en
Inventor
Said M Sebti
Andrew D Hamilton
James Turkson
Richard Jove
Original Assignee
Univ South Florida
Univ Yale
Said M Sebti
Andrew D Hamilton
James Turkson
Richard Jove
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, Univ Yale, Said M Sebti, Andrew D Hamilton, James Turkson, Richard Jove filed Critical Univ South Florida
Publication of WO2008070833A2 publication Critical patent/WO2008070833A2/en
Publication of WO2008070833A9 publication Critical patent/WO2008070833A9/en
Publication of WO2008070833A3 publication Critical patent/WO2008070833A3/en
Priority to US12/480,376 priority Critical patent/US8153596B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention display selective inhibition of specific STAT isoform homo-dimerization. The peptidomimetic probes of STAT1 function, described herein, provide the means to preferentially inhibit STAT1 over STAT3 through the exploration of the C-terminus.
PCT/US2007/086779 2006-12-07 2007-12-07 Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs WO2008070833A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/480,376 US8153596B2 (en) 2006-12-07 2009-06-08 Use of SH2 STAT3/STAT1 peptidomimetics as anticancer drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86901506P 2006-12-07 2006-12-07
US60/869,015 2006-12-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/480,376 Continuation US8153596B2 (en) 2006-12-07 2009-06-08 Use of SH2 STAT3/STAT1 peptidomimetics as anticancer drugs

Publications (3)

Publication Number Publication Date
WO2008070833A2 WO2008070833A2 (en) 2008-06-12
WO2008070833A9 WO2008070833A9 (en) 2008-08-28
WO2008070833A3 true WO2008070833A3 (en) 2008-10-16

Family

ID=39493096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086779 WO2008070833A2 (en) 2006-12-07 2007-12-07 Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs

Country Status (2)

Country Link
US (1) US8153596B2 (en)
WO (1) WO2008070833A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163423A2 (en) * 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US9765099B2 (en) * 2013-05-08 2017-09-19 Board Of Regents, The University Of Texas System STAT6 inhibitors
US20190375787A1 (en) * 2016-11-28 2019-12-12 Instytut Homeostazy Sp. Z O.O. Peptidomimetics and their use in therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof

Also Published As

Publication number Publication date
WO2008070833A2 (en) 2008-06-12
US8153596B2 (en) 2012-04-10
US20090318367A1 (en) 2009-12-24
WO2008070833A9 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
EP4006030A3 (en) Methods and compositions for inhibiting the interaction of menin with mll proteins
CO2018006299A2 (en) Novel compounds
MX2021010482A (en) Compounds and methods for the enhanced degradation of targeted proteins.
MX2019004561A (en) Dual inhibitors of vista and pd-1 pathways.
MX2017007629A (en) Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same.
UY31145A1 (en) DERIVED FROM 17B + CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, ITS USE AND MEDICATION CONTAINING IT
CL2012003680A1 (en) Compounds derived from (1,8) 2,4 diaryl naphthyridines substituted kinase inhibitors; its procedure for obtaining; pharmaceutical composition; and its use for the treatment and / or prevention of cancer, tumor, malignant tumors, among others; Pharmaceutical kit
MX2022009478A (en) Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase.
BR112012008385A2 (en) p13 kinase inhibitors and their use.
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2008115262A3 (en) Hsp90 inhibitors containing a zinc binding moiety
WO2009054878A8 (en) Compositions and methods for the treatment of neoplasia
CL2008000020A1 (en) Compounds derived from substituted 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and malignant tumors.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
CL2008000021A1 (en) Compounds derived from 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and cancer.
MX2020005078A (en) Novel cytoprotective drugs.
CL2011001215A1 (en) Compounds derived from pyrimidine, tyrosine kinase inhibitors; pharmaceutical compositions comprising them; and its use in the treatment and / or prevention of cancer, inflammatory diseases and autoimmune diseases.
CL2011002300A1 (en) Compounds derived from 5-substituted 2,4-diamiropyrimidines ptk2 kinase inhibitors; pharmaceutical preparations; and its use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
EP3103476A3 (en) Antibodies against a proliferating inducing ligand (april)
WO2015063747A3 (en) Peptide inhibitors of tead/yap-taz interaction
WO2008048680A3 (en) Notch 2 signaling as a breast cancer suppressor pathway
WO2008070833A3 (en) Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs
WO2018054989A9 (en) Benzoimidazole derivatives as anticancer agents
BR112014019704A8 (en) C-TERMINAL HSP90-INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND USE THEREOF FOR THE TREATMENT OR PREVENTION OF A NEURODEGENERATIVE DISORDER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07865379

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07865379

Country of ref document: EP

Kind code of ref document: A2